<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04413357</url>
  </required_header>
  <id_info>
    <org_study_id>19.01.US.HCN</org_study_id>
    <nct_id>NCT04413357</nct_id>
  </id_info>
  <brief_title>Glycemic Response in Persons With Type 2 Diabetes</brief_title>
  <official_title>Plasma Glucose and Insulin Response in Persons With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized crossover design with nutrition supplement interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized crossover design with three oral nutrition supplement
      interventions. The subjects will be randomized to one of three interventions on three
      separate study days, one week apart.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be a randomized crossover design. The subjects will be randomized to one of three interventions on three separate study days, one week apart.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Site pharmacy will not be blinded to product assignment, study staff and participants will be blinded to product assignment. Product will be provided in unlabeled cups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the blood glucose curve</measure>
    <time_frame>Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes</time_frame>
    <description>Area under the blood glucose curve (AUC 0-240 minutes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the insulin curves</measure>
    <time_frame>Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes</time_frame>
    <description>Area under the insulin curves (AUC 0-240)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulinogenic index</measure>
    <time_frame>Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes</time_frame>
    <description>Insulinogenic index [Change in Ins30/Change in Glu30]</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Oral Nutrition Supplement A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Nutrition Supplement B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Nutrition Supplement C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Nutrition Supplement</intervention_name>
    <description>The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition.</description>
    <arm_group_label>Oral Nutrition Supplement A</arm_group_label>
    <arm_group_label>Oral Nutrition Supplement B</arm_group_label>
    <arm_group_label>Oral Nutrition Supplement C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-75 years

          -  Type 2 diabetes controlled with diet or diet and metformin (Glucophage)

          -  Hemoglobin A1C less than 9.0%

          -  Fasting blood glucose less than 180 mg

          -  Hematocrit levels within normal limits

          -  Having obtained his/her informed consent

        Exclusion Criteria:

          -  Abnormal thyroid function

          -  Creatinine &gt;2.0 mg/dl

          -  Potassium &lt;3.5 mEq/l

          -  Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting

          -  Currently unstable diabetes or under treatment for cancer, heart disease, renal
             disease

          -  Unable to give informed consent or follow instructions

          -  Current insulin therapy or insulin therapy within the past month

          -  Patient who are pregnant

          -  Allergies to milk, soy or any component of the test product

          -  Patient who in the investigators assessment cannot be expected to comply with
             treatment

          -  Currently participating or having participated in another clinical trial

          -  Patients with anemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krysmaru Araujo Torres, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nestle Health Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

